OptimizeRx (NASDAQ:OPRX) Stock Gets Price Target Reduction from Stifel Nicolaus

OptimizeRx (NASDAQ:OPRX) had its price objective trimmed by Stifel Nicolaus from $12.00 to $11.00 in a research note published on Thursday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other equities research analysts also recently weighed in on OPRX. Citigroup reissued a “market outperform” rating on shares of OptimizeRx in a research note on Tuesday, October 27th. Wall Street Zen cut shares of OptimizeRx from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 20th. Weiss Ratings upgraded shares of OptimizeRx from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, August 25th. Citizens Jmp upped their price target on shares of OptimizeRx from $9.00 to $11.00 and gave the company a “market outperform” rating in a report on Friday, August 14th. Finally, UBS Group set a $11.00 target price on OptimizeRx in a research report on Friday, August 14th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, OptimizeRx currently has a consensus rating of “Moderate Buy” and an average target price of $11.21.

OptimizeRx Trading Down 17.2%

Shares of OptimizeRx stock traded down $1.53 on Thursday, reaching $7.34. The company had a trading volume of 611,439 shares, compared to its average volume of 210,704. The firm has a market cap of $138.29 million, a price-to-earnings ratio of 29.36 and a beta of 1.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.06 and a quick ratio of 5.58. The firm’s 50-day moving average price is $8.43 and its two-hundred day moving average price is $7.20. OptimizeRx has a 1 year low of $4.54 and a 1 year high of $15.59.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Wednesday, November 11th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.04. The company had revenue of $21.61 million for the quarter, compared to analyst estimates of $21.19 million. OptimizeRx had a return on equity of 9.58% and a net margin of 5.33%. As a group, research analysts predict that OptimizeRx will post 0.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP boosted its position in OptimizeRx by 183.2% during the 3rd quarter. Marshall Wace LLP now owns 459,362 shares of the company’s stock valued at $3,836,000 after acquiring an additional 297,176 shares in the last quarter. AWM Investment Company Inc. purchased a new position in shares of OptimizeRx in the 2nd quarter valued at $1,375,000. Royce & Associates LP increased its holdings in shares of OptimizeRx by 20.7% in the 3rd quarter. Royce & Associates LP now owns 1,315,057 shares of the company’s stock valued at $10,981,000 after acquiring an additional 225,659 shares during the period. Tocqueville Asset Management L.P. bought a new position in shares of OptimizeRx in the 3rd quarter worth $1,670,000. Finally, Segall Bryant & Hamill LLC bought a new position in shares of OptimizeRx in the 1st quarter worth $1,185,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx is a healthcare technology company that connects life sciences companies with healthcare professionals and patients through digital communications. Its platform uses channels such as electronic health records and other clinical workflows to deliver relevant information at the point of care. The company’s services support programs for medication access and affordability, patient education and engagement, and communication between healthcare providers and life sciences organizations. OptimizeRx also provides tools intended to help life sciences companies reach clinicians and patients through digital channels.